Compare PPL & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PPL | INSM |
|---|---|---|
| Founded | 1920 | 1988 |
| Country | United States | United States |
| Employees | 6546 | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.7B | 23.0B |
| IPO Year | 2007 | 2000 |
| Metric | PPL | INSM |
|---|---|---|
| Price | $35.47 | $107.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 24 |
| Target Price | $41.08 | ★ $201.17 |
| AVG Volume (30 Days) | ★ 9.2M | 3.6M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.95% | N/A |
| EPS Growth | ★ 32.50 | N/A |
| EPS | ★ 1.59 | N/A |
| Revenue | ★ $9,042,000,000.00 | N/A |
| Revenue This Year | $7.23 | $182.31 |
| Revenue Next Year | $5.85 | $65.19 |
| P/E Ratio | $22.52 | ★ N/A |
| Revenue Growth | ★ 6.85 | N/A |
| 52 Week Low | $33.17 | $90.39 |
| 52 Week High | $40.11 | $212.75 |
| Indicator | PPL | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 44.82 | 49.22 |
| Support Level | $34.91 | $98.90 |
| Resistance Level | $36.99 | $119.54 |
| Average True Range (ATR) | 0.71 | 4.44 |
| MACD | -0.06 | -0.09 |
| Stochastic Oscillator | 10.29 | 23.15 |
PPL is a holding company of regulated utilities in Pennsylvania, Kentucky, and Rhode Island. The Pennsylvania regulated delivery and transmission segment distributes electricity to customers in central and eastern Pennsylvania. In Kentucky, LG&E and KU are involved in regulated electricity generation, transmission, and distribution. LG&E also provides regulated natural gas distribution. Rhode Island Energy operates electric and gas utilities in the state.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.